ABSTRACT
Thrombospondin-1 (TSP-1) is released by platelets upon activation and can increase platelet activation, but its role in hemostasis in vivo is unclear. We show that TSP-1 is a critical mediator of hemostasis that promotes platelet activation by modulating inhibitory cyclic adenosine monophosphate (cAMP) signaling. Genetic deletion of TSP-1 did not affect platelet activation in vitro, but in vivo models of hemostasis and thrombosis showed that TSP-1-deficient mice had prolonged bleeding, defective thrombosis, and increased sensitivity to the prostacyclin mimetic iloprost. Adoptive transfer of wild-type (WT) but not TSP-1-/- platelets ameliorated the thrombotic phenotype, suggesting a key role for platelet-derived TSP-1. In functional assays, TSP-1-deficient platelets showed an increased sensitivity to cAMP signaling, inhibition of platelet aggregation, and arrest under flow by prostacyclin (PGI2). Plasma swap experiments showed that plasma TSP-1 did not correct PGI2 hypersensitivity in TSP-1-/- platelets. By contrast, incubation of TSP-1-/- platelets with releasates from WT platelets or purified TSP-1, but not releasates from TSP-1-/- platelets, reduced the inhibitory effects of PGI2. Activation of WT platelets resulted in diminished cAMP accumulation and downstream signaling, which was associated with increased activity of the cAMP hydrolyzing enzyme phosphodiesterase 3A (PDE3A). PDE3A activity and cAMP accumulation were unaffected in platelets from TSP-1-/- mice. Platelets deficient in CD36, a TSP-1 receptor, showed increased sensitivity to PGI2/cAMP signaling and diminished PDE3A activity, which was unaffected by platelet-derived or purified TSP-1. This scenario suggests that the release of TSP-1 regulates hemostasis in vivo through modulation of platelet cAMP signaling at sites of vascular injury.
Subject(s)
Blood Platelets/physiology , Cyclic AMP/physiology , Hemorrhagic Disorders/genetics , Hemostasis/physiology , Thrombospondin 1/physiology , Animals , Bleeding Time , Blood Platelets/drug effects , CD36 Antigens/deficiency , CD36 Antigens/physiology , Cells, Cultured , Chlorides/toxicity , Cyclic Nucleotide Phosphodiesterases, Type 3/metabolism , Cytoplasmic Granules/metabolism , Epoprostenol/physiology , Ferric Compounds/toxicity , Humans , Iloprost/pharmacology , Mice , Mice, Inbred C57BL , Platelet Transfusion , Second Messenger Systems/physiology , Thrombosis/chemically induced , Thrombosis/prevention & control , Thrombospondin 1/deficiency , Thrombospondin 1/pharmacologyABSTRACT
OBJECTIVE: Hyperleptinemia, hallmark of obesity, is a putative pathophysiologic trigger for atherosclerosis. We previously reported a stimulatory effect of leptin on TSP-1 (thrombospondin-1) expression, a proatherogenic matricellular protein implicated in atherogenesis. However, a causal role of TSP-1 in leptin-driven atherosclerosis remains unknown. Approach and Results: Seventeen-weeks-old ApoE-/- and TSP-1-/-/ApoE-/- double knockout mice, on normocholesterolemic diet, were treated with or without murine recombinant leptin (5 µg/g bwt, IP) once daily for 3 weeks. Using aortic root morphometry and en face lesion assay, we found that TSP-1 deletion abrogated leptin-stimulated lipid-filled lesion burden, plaque area, and collagen accumulation in aortic roots of ApoE-/- mice, shown via Oil red O, hematoxylin and eosin, and Masson trichrome staining, respectively. Immunofluorescence microscopy of aortic roots showed that TSP-1 deficiency blocked leptin-induced inflammatory and smooth muscle cell abundance as well as cellular proliferation in ApoE-/- mice. Moreover, these effects were concomitant to changes in VLDL (very low-density lipoprotein)-triglyceride and HDL (high-density lipoprotein)-cholesterol levels. Immunoblotting further revealed reduced vimentin and pCREB (phospho-cyclic AMP response element-binding protein) accompanied with augmented smooth muscle-myosin heavy chain expression in aortic vessels of leptin-treated double knockout versus leptin-treated ApoE-/-; also confirmed in aortic smooth muscle cells from the mice genotypes, incubated ± leptin in vitro. Finally, TSP-1 deletion impeded plaque burden in leptin-treated ApoE-/- on western diet, independent of plasma lipid alterations. CONCLUSIONS: The present study provides evidence for a protective effect of TSP-1 deletion on leptin-stimulated atherogenesis. Our findings suggest a regulatory role of TSP-1 on leptin-induced vascular smooth muscle cell phenotypic transition and inflammatory lesion invasion. Collectively, these results underscore TSP-1 as a potential target of leptin-induced vasculopathy.
Subject(s)
Aortic Diseases/prevention & control , Atherosclerosis/prevention & control , Muscle, Smooth, Vascular/metabolism , Myocytes, Smooth Muscle/metabolism , Thrombospondin 1/deficiency , Animals , Aorta/metabolism , Aorta/pathology , Aortic Diseases/chemically induced , Aortic Diseases/metabolism , Aortic Diseases/pathology , Atherosclerosis/chemically induced , Atherosclerosis/metabolism , Atherosclerosis/pathology , Cell Differentiation , Cell Proliferation , Cells, Cultured , Collagen/metabolism , Diet, High-Fat , Disease Models, Animal , Leptin , Male , Mice, Inbred C57BL , Mice, Knockout, ApoE , Muscle, Smooth, Vascular/pathology , Myocytes, Smooth Muscle/pathology , Plaque, Atherosclerotic , Signal Transduction , Thrombospondin 1/geneticsABSTRACT
OBJECTIVE: Abdominal aortic aneurysm is characterized by the progressive loss of aortic integrity and accumulation of inflammatory cells primarily macrophages. We previously reported that global deletion of matricellular protein TSP1 (thrombospondin-1) protects mice from aneurysm formation. The objective of the current study is to investigate the cellular and molecular mechanisms underlying TSP1's action in aneurysm. Approach and Results: Using RNA fluorescent in situ hybridization, we identified macrophages being the major source of TSP1 in human and mouse aneurysmal tissues, accounting for over 70% of cells that actively expressed Thbs1 mRNA. Lack of TSP1 in macrophages decreased solution-based gelatinase activities by elevating TIMP1 (tissue inhibitor of metalloproteinases-1) without affecting the major MMPs (matrix metalloproteinases). Knocking down Timp1 restored the ability of Thbs1-/- macrophages to invade matrix. Finally, we generated Thbs1flox/flox mice and crossed them with Lyz2-cre mice. In the CaCl2-induced model of abdominal aortic aneurysm, lacking TSP1 in myeloid cells was sufficient to protect mice from aneurysm by reducing macrophage accumulation and preserving aortic integrity. CONCLUSIONS: TSP1 contributes to aneurysm pathogenesis, at least in part, by suppressing TIMP1 expression, which subsequently enables inflammatory macrophages to infiltrate vascular tissues.
Subject(s)
Aorta, Abdominal/metabolism , Aortic Aneurysm, Abdominal/metabolism , Macrophages/metabolism , Thrombospondin 1/metabolism , Tissue Inhibitor of Metalloproteinase-1/metabolism , Animals , Aorta, Abdominal/pathology , Aortic Aneurysm, Abdominal/genetics , Aortic Aneurysm, Abdominal/pathology , Cells, Cultured , Dilatation, Pathologic , Disease Models, Animal , Down-Regulation , Humans , Macrophages/pathology , Male , Matrix Metalloproteinases/metabolism , Mice, Inbred C57BL , Mice, Knockout, ApoE , Signal Transduction , Thrombospondin 1/deficiency , Thrombospondin 1/genetics , Tissue Inhibitor of Metalloproteinase-1/geneticsABSTRACT
The protozoan parasite Trypanosoma cruzi is the causative agent of Chagas disease. This neglected tropical disease causes severe morbidity and mortality in endemic regions. About 30% of T. cruzi infected individuals will present with cardiac complications. Invasive trypomastigotes released from infected cells can be carried in the vascular endothelial system to infect neighboring and distant cells. During the process of cellular infection, the parasite induces host cells, to increase the levels of host thrombospondin-1 (TSP-1), to facilitate the process of infection. TSP-1 plays important roles in the functioning of vascular cells, including vascular endothelial cells with important implications in cardiovascular health. Many signal transduction pathways, including the yes-associated protein 1 (YAP)/transcriptional coactivator, with PDZ-binding motif (TAZ) signaling, which are upstream of TSP-1, have been linked to the pathophysiology of heart damage. The molecular mechanisms by which T. cruzi signals, and eventually infects, heart endothelial cells remain unknown. To evaluate the importance of TSP-1 expression in heart endothelial cells during the process of T. cruzi infection, we exposed heart endothelial cells prepared from Wild Type and TSP-1 Knockout mouse to invasive T. cruzi trypomastigotes at multiple time points, and evaluated changes in the hippo signaling cascade using immunoblotting and immunofluorescence assays. We found that the parasite turned off the hippo signaling pathway in TSP-1KO heart endothelial cells. The levels of SAV1 and MOB1A increased to a maximum of 2.70 ± 0.23 and 5.74 ± 1.45-fold at 3 and 6 h, respectively, in TSP-1KO mouse heart endothelial cells (MHEC), compared to WT MHEC, following a parasite challenge. This was accompanied by a significant continuous increase in the nuclear translocation of downstream effector molecule YAP, to a maximum mean nuclear fluorescence intensity of 10.14 ± 0.40 at 6 h, compared to wild type cells. Furthermore, we found that increased nuclear translocated YAP significantly colocalized with the transcription co-activator molecule pan-TEAD, with a maximum Pearson's correlation coefficient of 0.51 ± 0.06 at 6 h, compared to YAP-Pan-TEAD colocalization in the WT MHEC, which decreased significantly, with a minimum Pearson's correlation coefficient of 0.30 ± 0.01 at 6 h. Our data indicate that, during the early phase of infection, upregulated TSP-1 is essential for the regulation of the hippo signaling pathway. These studies advance our understanding of the molecular interactions occurring between heart endothelial cells and T. cruzi, in the presence and absence of TSP-1, providing insights into processes linked to parasite dissemination and pathogenesis.
Subject(s)
Active Transport, Cell Nucleus/physiology , Endothelial Cells/parasitology , Myoblasts/parasitology , Myocardium/cytology , Protozoan Proteins/physiology , Thrombospondin 1/physiology , Trypanosoma cruzi/physiology , Adaptor Proteins, Signal Transducing/metabolism , Animals , Cell Cycle Proteins/metabolism , DNA-Binding Proteins/metabolism , Endothelial Cells/metabolism , Gene Knockout Techniques , Mice , Myoblasts/metabolism , Protein Serine-Threonine Kinases/metabolism , Rats , Signal Transduction/physiology , Thrombospondin 1/deficiency , Trans-Activators/physiologyABSTRACT
Thrombospondin-1 and 2 have each been implicated in collagen fibrillogenesis. We addressed the possibility that deficits in lysyl oxidase (LOX) contribute to the extracellular matrix (ECM) phenotype of TSP-deficient bone. We examined detergent insoluble (mature cross-linked) and soluble (newly secreted) ECM fractions prepared from diaphyseal cortical bone. Detergent-insoluble hydroxyproline content, an indicator of cross-linked collagen content and LOX function, was reduced in female TSP-deficient bones. In male diaphyses, only TSP2 deficiency affected insoluble hydroxyproline content. Western blot suggested that removal of the LOX-pro-peptide (LOPP), an indication of LOX activation, was not affected by TSP status. Instead, the distribution of pro-LOX and mature LOX between immature and mature ECM was altered by TSP-status. LOX was also examined in primary marrow-derived mesenchymal stem cells (MSC) treated with ascorbate. Relative LOPP levels were elevated compared to WT in MSC conditioned medium from female TSP-deficient mice. When cells were serum starved to limit LOX pro-peptide removal, pro-LOX levels were elevated in TSP2-/- cells compared to wild-type. This phenotype was associated with a transient increase in BMP1 levels in TSP2-/- conditioned medium. TSP2 was detected in bone tissue and osteoblast cell culture. TSP1 was only detected in insoluble ECM prepared from WT diaphyseal bone samples. Our data suggest that the trimeric thrombospondins contribute to bone matrix quality by regulating the distribution of pro and mature LOX between newly secreted, immature ECM and mature, cross-linked ECM.
Subject(s)
Diaphyses/metabolism , Femur/metabolism , Peptides/metabolism , Protein-Lysine 6-Oxidase/metabolism , Thrombospondin 1/deficiency , Thrombospondins/deficiency , Animals , Bone Morphogenetic Protein 1/metabolism , Collagen/metabolism , Extracellular Matrix/metabolism , Female , Humans , Male , Mesenchymal Stem Cells , Mice, Inbred C57BL , Mice, Knockout , Thrombospondin 1/metabolism , Thrombospondins/metabolismABSTRACT
Chronic inflammation of the ocular surface poses a risk of vision impairment. The understanding of the molecular mechanisms that are involved in the inflammatory response is critical to identify novel molecular targets. Recently, thrombospondin-1 (TSP-1) has emerged as a key player in ocular surface homeostasis that efficiently activates the TGF-ß2 isoform that is predominantly expressed in the ocular mucosa. Here, the potential of the peptide derived from TSP-1 (KRFK), that can activate TGF-ß, is proposed as a potentially applicable therapeutic for chronic ocular surface inflammatory disorders. Our in vitro results confirm that the chosen peptide activates TGF-ß, reducing the expression of co-stimulatory molecules on dendritic cells, driving them towards a tolerogenic phenotype. For the in vivo studies, the TSP-1-/- mouse is used as a pre-clinical model of chronic ocular inflammation. We observe that the topical application of KRFK alters the peripheral balance of effectors by reducing the proportion of pathogenic Th1 and Th17 cells while increasing Treg cell proportion in cervical lymph nodes. In line with these findings, the development of chronic ocular surface inflammation is significantly prevented in KRFK-treated TSP-1-/- mice, as assessed by clinical parameters and inflammatory cytokine expression in conjunctival and lacrimal gland tissues. Together, our results identify the KRFK peptide as a novel therapeutic option to prevent the development of chronic inflammatory manifestations of the ocular surface.
Subject(s)
Anti-Inflammatory Agents/pharmacology , Endophthalmitis/etiology , Endophthalmitis/metabolism , Oligopeptides/pharmacology , Thrombospondin 1/deficiency , Transforming Growth Factor beta/metabolism , Animals , Biomarkers , CD4-Positive T-Lymphocytes/immunology , CD4-Positive T-Lymphocytes/metabolism , Chronic Disease , Dendritic Cells/drug effects , Dendritic Cells/immunology , Dendritic Cells/metabolism , Disease Models, Animal , Endophthalmitis/drug therapy , Endophthalmitis/pathology , Fibrosis , Immunohistochemistry , Mice , Mice, Knockout , Thrombospondin 1/genetics , Thrombospondin 1/metabolism , Transforming Growth Factor beta/chemistryABSTRACT
RATIONALE: Abnormal mechanosensing of smooth muscle cells (SMCs) resulting from the defective elastin-contractile units has been suggested to drive the formation of thoracic aortic aneurysms; however, the precise molecular mechanism has not been elucidated. OBJECTIVE: The aim of this study was to identify the crucial mediator(s) involved in abnormal mechanosensing and propagation of biochemical signals during the aneurysm formation and to establish a basis for a novel therapeutic strategy. METHODS AND RESULTS: We used a mouse model of postnatal ascending aortic aneurysms ( Fbln4SMKO; termed SMKO [SMC-specific knockout]), in which deletion of Fbln4 (fibulin-4) leads to disruption of the elastin-contractile units caused by a loss of elastic lamina-SMC connections. In this mouse, upregulation of Egr1 (early growth response 1) and angiotensin-converting enzyme leads to activation of Ang II (angiotensin II) signaling. Here, we showed that the matricellular protein, Thbs1 (thrombospondin-1), was highly upregulated in SMKO ascending aortas and in human thoracic aortic aneurysms. Thbs1 was induced by mechanical stretch and Ang II in SMCs, for which Egr1 was required, and reduction of Fbln4 sensitized the cells to these stimuli and led to higher expression of Egr1 and Thbs1. Deletion of Thbs1 in SMKO mice prevented the aneurysm formation in ≈80% of DKO (SMKO;Thbs1 knockout) animals and suppressed Ssh1 (slingshot-1) and cofilin dephosphorylation, leading to the formation of normal actin filaments. Furthermore, elastic lamina-SMC connections were restored in DKO aortas, and mechanical testing showed that structural and material properties of DKO aortas were markedly improved. CONCLUSIONS: Thbs1 is a critical component of mechanotransduction, as well as a modulator of elastic fiber organization. Maladaptive upregulation of Thbs1 results in disruption of elastin-contractile units and dysregulation of actin cytoskeletal remodeling, contributing to the development of ascending aortic aneurysms in vivo. Thbs1 may serve as a potential therapeutic target for treating thoracic aortic aneurysms.
Subject(s)
Aortic Aneurysm, Thoracic/metabolism , Mechanotransduction, Cellular , Muscle, Smooth, Vascular/metabolism , Thrombospondin 1/metabolism , Vascular Remodeling , Actin Cytoskeleton/metabolism , Actin Cytoskeleton/pathology , Aged , Aged, 80 and over , Animals , Aorta, Thoracic/metabolism , Aorta, Thoracic/pathology , Aortic Aneurysm, Thoracic/genetics , Aortic Aneurysm, Thoracic/pathology , Aortic Aneurysm, Thoracic/prevention & control , Cells, Cultured , Cofilin 2/metabolism , Dilatation, Pathologic , Disease Models, Animal , Early Growth Response Protein 1/metabolism , Elastic Tissue/metabolism , Elastic Tissue/pathology , Elastin/metabolism , Extracellular Matrix Proteins/deficiency , Extracellular Matrix Proteins/genetics , Female , Humans , Male , Mice, Knockout , Middle Aged , Muscle, Smooth, Vascular/pathology , Phosphoprotein Phosphatases/metabolism , Phosphorylation , Pressoreceptors/metabolism , Rats , Stress, Mechanical , Thrombospondin 1/deficiency , Thrombospondin 1/geneticsABSTRACT
Abnormal dendritic spine structure and function is one of the most prominent features associated with neurodevelopmental disorders including Down syndrome (DS). Defects in both spine morphology and spine density may underlie alterations in neuronal and synaptic plasticity, ultimately affecting cognitive ability. Here we briefly examine the role of astrocytes in spine alterations and more specifically the involvement of astrocyte-secreted thrombospondin 1 (TSP-1) deficits in spine and synaptic pathology in DS.
Subject(s)
Dendritic Spines/pathology , Down Syndrome/pathology , Synapses/pathology , Thrombospondin 1/deficiency , Animals , Disease Models, Animal , Down Syndrome/etiology , HumansABSTRACT
Background: Thrombospondin-1 (TSP-1) is an extracellular matrix protein that plays multiple physiological and pathophysiological roles in the brain. Experimental reports suggest that TSP-1 may have an adverse role in neuronal function recovery under certain injury conditions. However, the roles of TSP-1 in traumatic brain injury (TBI) have not been elucidated. In this study we for the first time investigated the roles of TSP-1 in a controlled cortical impact (CCI) model of TBI in TSP-1 knockout (TSP-1 KO) and wild type (WT) mice. Methods: We examined blood brain-barrier (BBB) damage using at 1 day post-TBI by measuring Evans Blue leakage, and neurological functional recovery at 3 weeks post-TBI by measuring neurological severity score (NSS), wire gripping, corner test and Morris Water Maze (MWM). Mechanistically, we quantified pro-angiogenic biomarkers including cerebral vessel density, vascular endothelial growth factors (VEGF) and angiopoietin-1 (Ang-1) protein expression, synaptic biomarker synaptophysin, and synaptogenesis marker brain-derived neurotrophic factor (BDNF) protein expression in contralateral and ipsilateral (peri-lesion) cortex at 21 days after TBI using immunohistochemistry and Western Blot. Results: TSP-1 is upregulated at early phase of TBI in WT mice. Compared to WT mice, TSP-1 KO (1) significantly worsened TBI-induced BBB leakage at 1 day after TBI; (2) had similar lesion size as WT mice at 3 weeks after TBI; (3) exhibited a significantly worse neurological deficits in motor and cognitive functions; (4) had no significant difference in cerebral vessel density, but significant increase of VEGF and Ang-1 protein expressions in peri-lesion cortex; (5) significantly increased BDNF but not synaptophysin protein level in peri-lesion cortex compared to sham, but both synaptophysin and BDNF expressions were significantly decreased in contralateral cortex compared to WT. Conclusion: Our results suggest that TSP-1 may be beneficial for maintaining BBB integrity in the early phase and functional recovery in late phase after TBI. The molecular mechanisms of TSP-1 in early BBB pathophysiology, and long-term neurological function recovery after TBI need to be further investigated.
Subject(s)
Blood-Brain Barrier/pathology , Brain Injuries/pathology , Cerebral Cortex/physiopathology , Cognition/physiology , Thrombospondin 1/deficiency , Angiopoietin-1/metabolism , Animals , Biomarkers/analysis , Brain-Derived Neurotrophic Factor/metabolism , Cerebral Cortex/blood supply , Cerebral Cortex/injuries , Cerebral Cortex/metabolism , Disease Models, Animal , Maze Learning , Mice , Mice, Inbred C57BL , Mice, Knockout , Neovascularization, Physiologic , Recovery of Function/physiology , Synaptophysin/metabolism , Thrombospondin 1/genetics , Time Factors , Up-Regulation , Vascular Endothelial Growth Factor A/metabolismABSTRACT
BACKGROUND: Arterial stiffness and wall shear stress are powerful determinants of cardiovascular health, and arterial stiffness is associated with increased cardiovascular mortality. Low and oscillatory wall shear stress, termed disturbed flow (d-flow), promotes atherosclerotic arterial remodeling, but the relationship between d-flow and arterial stiffness is not well understood. The objective of this study was to define the role of d-flow on arterial stiffening and discover the relevant signaling pathways by which d-flow stiffens arteries. METHODS: D-flow was induced in the carotid arteries of young and old mice of both sexes. Arterial stiffness was quantified ex vivo with cylindrical biaxial mechanical testing and in vivo from duplex ultrasound and compared with unmanipulated carotid arteries from 80-week-old mice. Gene expression and pathway analysis was performed on endothelial cell-enriched RNA and validated by immunohistochemistry. In vitro testing of signaling pathways was performed under oscillatory and laminar wall shear stress conditions. Human arteries from regions of d-flow and stable flow were tested ex vivo to validate critical results from the animal model. RESULTS: D-flow induced arterial stiffening through collagen deposition after partial carotid ligation, and the degree of stiffening was similar to that of unmanipulated carotid arteries from 80-week-old mice. Intimal gene pathway analyses identified transforming growth factor-ß pathways as having a prominent role in this stiffened arterial response, but this was attributable to thrombospondin-1 (TSP-1) stimulation of profibrotic genes and not changes to transforming growth factor-ß. In vitro and in vivo testing under d-flow conditions identified a possible role for TSP-1 activation of transforming growth factor-ß in the upregulation of these genes. TSP-1 knockout animals had significantly less arterial stiffening in response to d-flow than wild-type carotid arteries. Human arteries exposed to d-flow had similar increases TSP-1 and collagen gene expression as seen in our model. CONCLUSIONS: TSP-1 has a critical role in shear-mediated arterial stiffening that is mediated in part through TSP-1's activation of the profibrotic signaling pathways of transforming growth factor-ß. Molecular targets in this pathway may lead to novel therapies to limit arterial stiffening and the progression of disease in arteries exposed to d-flow.
Subject(s)
Thrombospondin 1/metabolism , Vascular Stiffness/physiology , Aging , Animals , Atrial Remodeling , Carotid Arteries/metabolism , Carotid Arteries/physiopathology , Cell Line , Collagen/genetics , Collagen/metabolism , Disease Models, Animal , Down-Regulation , Endothelium, Vascular/cytology , Endothelium, Vascular/metabolism , Female , Humans , Immunohistochemistry , Male , Mice , Mice, Inbred C57BL , Mice, Knockout , Protein Serine-Threonine Kinases/genetics , Protein Serine-Threonine Kinases/metabolism , RNA, Ribosomal, 18S/metabolism , Receptor, Transforming Growth Factor-beta Type I , Receptors, Transforming Growth Factor beta/genetics , Receptors, Transforming Growth Factor beta/metabolism , Shear Strength , Thrombospondin 1/deficiency , Thrombospondin 1/genetics , Transforming Growth Factor beta/metabolismABSTRACT
BACKGROUND: Thrombospondin-1 (TSP-1) is functionally important to intimal hyperplasia (IH) development. Statin drugs have beneficial pleiotropic effects, including reduced IH; however, the effect of statins on IH in a TSP-1-independent setting is unknown. HYPOTHESIS: Statins will be less effective in attenuating IH after vascular injury in TSP-1-null (Thbs1-/-) mice compared with wild-type (WT) mice. MATERIALS AND METHODS: Carotid artery ligation was performed on WT and Thbs1-/- mice. Each strain was divided into two groups: no statin control or standard chow containing fluvastatin (10 or 40 mg/kg/d). After 28 d, analysis included morphometric analysis and real-time quantitative reverse transcription polymerase chain reaction on the arteries and enzyme-linked immunosorbent assay on plasma (TSP-1 WT, TSP-2 WT, and Thbs1-/-). Comparisons were made by analysis of variance, with P < 0.05 considered significant. RESULTS: In no statin controls, WT mice had more IH than Thbs1-/- mice (0.46 ± 0.09 versus 0.15 ± 0.04). Fluvastatin reduced IH in the WT (0.46 ± 0.09 versus 0.23 ± 0.06), but not in Thbs1-/- groups (0.15 ± 0.04 versus 0.22 ± 0.07). No difference in IH existed between Thbs1-/- no statin controls and fluvastatin WT and Thbs1-/- groups. Statin dose did not affect IH. TSP-1 plasma levels were increased in fluvastatin WT. TSP-2 levels were decreased in fluvastatin WT and elevated in fluvastatin Thbs1-/-. Fluvastatin had no effect on tissue Thbs1 or Thbs2 gene expression. CONCLUSIONS: TSP-1 is necessary for robust IH after arterial injury. Because fluvastatin had no effect on IH in Thbs1-/-, the data suggest that the statin effect on IH may be largely TSP-1 dependent. Both statins and the presence of TSP-1 affect TSP-1 and TSP-2 plasma levels.
Subject(s)
Carotid Arteries/pathology , Fatty Acids, Monounsaturated/therapeutic use , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Hyperplasia/prevention & control , Indoles/therapeutic use , Thrombospondin 1/metabolism , Tunica Intima/pathology , Animals , Biomarkers/metabolism , Carotid Arteries/drug effects , Carotid Arteries/metabolism , Dose-Response Relationship, Drug , Enzyme-Linked Immunosorbent Assay , Fatty Acids, Monounsaturated/pharmacology , Fluvastatin , Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology , Hyperplasia/metabolism , Indoles/pharmacology , Male , Mice , Mice, Knockout , Real-Time Polymerase Chain Reaction , Reverse Transcriptase Polymerase Chain Reaction , Thrombospondin 1/deficiency , Tunica Intima/drug effects , Tunica Intima/metabolismABSTRACT
Abdominal aortic aneurysm (AAA) is a common age-related vascular disease characterized by progressive weakening and dilatation of the aortic wall. Thrombospondin-1 (TSP-1; gene Thbs1) is a member of the matricellular protein family important in the control of extracellular matrix (ECM) remodelling. In the present study, the association of serum TSP-1 concentration with AAA progression was assessed in 276 men that underwent repeated ultrasound for a median 5.5 years. AAA growth was negatively correlated with serum TSP-1 concentration (Spearman's rho -0.129, P=0.033). Men with TSP-1 in the highest quartile had a reduced likelihood of AAA growth greater than median during follow-up (OR: 0.40; 95% confidence interval (CI): 0.19-0.84, P=0.016, adjusted for other risk factors). Immunohistochemical staining for TSP-1 was reduced in AAA body tissues compared with the relatively normal AAA neck. To further assess the role of TSP-1 in AAA initiation and progression, combined TSP-1 and apolipoprotein deficient (Thbs1-/-ApoE-/-, n=20) and control mice (ApoE-/-, n=20) were infused subcutaneously with angiotensin II (AngII) for 28 days. Following AngII infusion, Thbs1-/- ApoE-/- mice had larger AAAs by ultrasound (P=0.024) and ex vivo morphometry measurement (P=0.006). The Thbs1-/-ApoE-/- mice also showed increased elastin filament degradation along with elevated systemic levels and aortic expression of matrix metalloproteinase (MMP)-9. Suprarenal aortic segments and vascular smooth muscle cells (VSMCs) isolated from Thbs1-/-ApoE-/- mice showed reduced collagen 3A1 gene expression. Furthermore, Thbs1-/-ApoE-/- mice had reduced aortic expression of low-density lipoprotein (LDL) receptor-related protein 1. Collectively, findings from the present study suggest that TSP-1 deficiency promotes maladaptive remodelling of the ECM leading to accelerated AAA progression.
Subject(s)
Angiotensin II , Aorta, Abdominal/metabolism , Aortic Aneurysm, Abdominal/metabolism , Thrombospondin 1/blood , Thrombospondin 1/deficiency , Animals , Aorta, Abdominal/diagnostic imaging , Aorta, Abdominal/pathology , Aortic Aneurysm, Abdominal/blood , Aortic Aneurysm, Abdominal/chemically induced , Aortic Aneurysm, Abdominal/prevention & control , Apolipoproteins E/deficiency , Apolipoproteins E/genetics , Biomarkers/blood , Cells, Cultured , Collagen Type III/genetics , Collagen Type III/metabolism , Disease Models, Animal , Disease Progression , Elastin/metabolism , Genetic Predisposition to Disease , Humans , Low Density Lipoprotein Receptor-Related Protein-1 , Male , Matrix Metalloproteinase 9/genetics , Matrix Metalloproteinase 9/metabolism , Mice, Knockout , Odds Ratio , Phenotype , Proteolysis , Receptors, LDL/genetics , Receptors, LDL/metabolism , Risk Factors , Thrombospondin 1/genetics , Time Factors , Tumor Suppressor Proteins/genetics , Tumor Suppressor Proteins/metabolism , Ultrasonography , Vascular RemodelingABSTRACT
AIMS: Thrombospondin-1 (TSP1) is a ligand for CD47 and TSP1-/- mice are protected from pulmonary hypertension (PH). We hypothesized the TSP1-CD47 axis is upregulated in human PH and promotes pulmonary arterial vasculopathy. METHODS AND RESULTS: We analyzed the molecular signature and functional response of lung tissue and distal pulmonary arteries (PAs) from individuals with (n = 23) and without (n = 16) PH. Compared with controls, lungs and distal PAs from PH patients showed induction of TSP1-CD47 and endothelin-1/endothelin A receptor (ET-1/ETA) protein and mRNA. In control PAs, treatment with exogenous TSP1 inhibited vasodilation and potentiated vasoconstriction to ET-1. Treatment of diseased PAs from PH patients with a CD47 blocking antibody improved sensitivity to vasodilators. Hypoxic wild type (WT) mice developed PH and displayed upregulation of pulmonary TSP1, CD47, and ET-1/ETA concurrent with down regulation of the transcription factor cell homolog of the v-myc oncogene (cMyc). In contrast, PH was attenuated in hypoxic CD47-/- mice while pulmonary TSP1 and ET-1/ETA were unchanged and cMyc was overexpressed. In CD47-/- pulmonary endothelial cells cMyc was increased and ET-1 decreased. In CD47+/+ cells, forced induction of cMyc suppressed ET-1 transcript, whereas suppression of cMyc increased ET-1 signaling. Furthermore, disrupting TSP1-CD47 signaling in pulmonary smooth muscle cells abrogated ET-1-stimulated hypertrophy. Finally, a CD47 antibody given 2 weeks after monocrotaline challenge in rats upregulated pulmonary cMyc and improved aberrations in PH-associated cardiopulmonary parameters. CONCLUSIONS: In pre-clinical models of PH CD47 targets cMyc to increase ET-1 signaling. In clinical PH TSP1-CD47 is upregulated, and in both, contributes to pulmonary arterial vasculopathy and dysfunction.
Subject(s)
Arterial Pressure , CD47 Antigen/metabolism , Hypertension, Pulmonary/metabolism , Pulmonary Artery/metabolism , Signal Transduction , Thrombospondin 1/metabolism , Adult , Aged , Animals , CD47 Antigen/genetics , Case-Control Studies , Cell Line , Disease Models, Animal , Endothelial Cells/metabolism , Endothelin-1/metabolism , Female , Genetic Predisposition to Disease , Humans , Hypertension, Pulmonary/genetics , Hypertension, Pulmonary/physiopathology , Hypertension, Pulmonary/prevention & control , Male , Mice, Inbred C57BL , Mice, Knockout , Middle Aged , Phenotype , Proto-Oncogene Proteins c-myc/genetics , Proto-Oncogene Proteins c-myc/metabolism , Pulmonary Artery/physiopathology , RNA Interference , Rats , Thrombospondin 1/deficiency , Thrombospondin 1/genetics , Transfection , Up-Regulation , Vasoconstriction , Vasodilation , Young AdultABSTRACT
Accumulating evidence suggests that thrombospondin 1 (TSP1) is an important player in diabetic nephropathy. However, the role of TSP1 in podocyte injury and the development of non-diabetic proteinuric kidney disease is largely unknown. In the current study, by using a well-established podocyte injury model (adriamycin-induced nephropathy mouse model), we examined the contribution of TSP1 to the development of proteinuric kidney disease. We found that TSP1 was up-regulated in the glomeruli, notably in podocytes, in adriamycin injected mice before the onset of proteinuria. ADR treatment also stimulated TSP1 expression in cultured human podocytes in vitro. Moreover, increased TSP1 mediated ADR-induced podocyte apoptosis and actin cytoskeleton disorganization. This TSP1's effect was through a CD36-dependent mechanism and involved in the stimulation of p38MAPK pathway. Importantly, in vivo data demonstrated that TSP1 deficiency protected mice from ADR induced podocyte loss and foot process effacement. ADR induced proteinuria, glomerulosclerosis, renal macrophage infiltration and inflammation was also attenuated in TSP1 deficient mice. Taken together, these studies provide new evidence that TSP1 contributes to the development of non-diabetic proteinuric kidney disease by stimulating podocyte injury and the progression of renal inflammation.
Subject(s)
Proteinuria/genetics , Thrombospondin 1/genetics , Actin Cytoskeleton/metabolism , Animals , Apoptosis , Cell Line , Cells, Cultured , Doxorubicin/toxicity , Humans , MAP Kinase Signaling System , Male , Mice , Mice, Inbred C57BL , Podocytes/drug effects , Podocytes/metabolism , Proteinuria/etiology , Proteinuria/metabolism , Thrombospondin 1/deficiency , Thrombospondin 1/metabolism , p38 Mitogen-Activated Protein Kinases/metabolismABSTRACT
Methotrexate (MTX) is a widely used treatment for inflammatory diseases such as rheumatoid arthritis and psoriasis, based on the concept that it is immunosuppressive. Its mechanism of action, however, remains unclear, although it is thought to depend on adenosine. Caffeine and theophylline, which have several targets including adenosine receptors, have been shown to suppress the beneficial clinical effects of MTX. Here we show that MTX and caffeine and theophylline differentially affect a motogenic T-cell mechanism driven by endogenous thrombospondin-1 (TSP-1) and its receptor, low density lipoprotein receptor-related protein 1 (LRP1). MTX stimulated TSP-1 expression and the motogenic TSP-1/TSP-1 receptor mechanism in primary human T cells, hence mimicking IL-2 and CXCL12, which similar to MTX, dampen inflammatory disease. SiRNA-mediated gene silencing of TSP-1 and LRP1 inhibited this stimulatory effect. Caffeine and theophylline inhibited the TSP-1/TSP-1 receptor mechanism by inhibiting LRP1 expression. These results indicate that the effect of MTX on T cells is immunoregulatory rather than immunosuppressive, and suggest a pathway dependent on TSP-1/TSP-1 receptor interactions for the regulation of immune responses.
Subject(s)
Caffeine/pharmacology , Gene Expression Regulation , Immunosuppressive Agents/pharmacology , Methotrexate/pharmacology , T-Lymphocytes/drug effects , T-Lymphocytes/physiology , Theophylline/pharmacology , Thrombospondin 1/metabolism , Cytokines/pharmacology , Gene Silencing , Humans , Low Density Lipoprotein Receptor-Related Protein-1/deficiency , Low Density Lipoprotein Receptor-Related Protein-1/genetics , Low Density Lipoprotein Receptor-Related Protein-1/metabolism , Methotrexate/antagonists & inhibitors , Mitogens/immunology , RNA, Small Interfering , T-Lymphocytes/immunology , Thrombospondin 1/deficiency , Thrombospondin 1/geneticsABSTRACT
Sjögren's syndrome is an autoimmune disease associated with inflammation of exocrine glands with clinical manifestations of dry eye and dry mouth. Dry eye in this disease involves inflammation of the ocular surface tissues - cornea and conjunctiva. While systemic blockade of adhesion molecules has been used to treat autoimmune diseases, the purpose of this study was to determine the therapeutic efficacy of topical application of an integrin α4 adhesion molecule antagonist in a mouse model of dry eye associated with Sjögren's syndrome. To assess this spontaneously developed ocular surface inflammation related to Sjögren's syndrome in TSP-1null mice (12 wks) was evaluated. Mice were treated with topical formulations containing 0.1% dexamethasone or 30 mg/ml GW559090 or vehicle control. Corneal fluorescein staining and conjunctival goblet cell density were assessed. Real-time PCR analysis was performed to assess expression of the inflammatory marker IL-1ß in the cornea and Tbet and RORγt in the draining lymph nodes. Ocular surface inflammation was detectable in TSP-1null mice (≥12 wk old), which resulted in increased corneal fluorescein staining indicative of corneal barrier disruption and reduced conjunctival goblet cell density. These changes were accompanied by increased corneal expression of IL-1ß as compared to WT controls and an altered balance of Th1 (Tbet) and Th17 (RORγt) markers in the draining lymph nodes. Topically applied dexamethasone and GW559090 significantly reduced corneal fluorescein staining compared to vehicle treatment (p = 0.023 and p < 0.001, respectively). This improved corneal barrier integrity upon adhesion molecule blockade was consistent with significantly reduced corneal expression of pro-inflammatory IL-1ß compared to vehicle treated groups (p < 0.05 for both treatments). Significant improvement in goblet cell density was also noted in mice treated with 0.1% dexamethasone and GW559090 (p < 0.05 for both). We conclude that similar to topical dexamethasone, topically administered GW559090 successfully improved corneal barrier integrity and inflammation in an established ocular surface disease associated with Sjögren's syndrome.
Subject(s)
Disease Models, Animal , Dry Eye Syndromes/prevention & control , Integrin alpha4beta1/antagonists & inhibitors , Phenylalanine/analogs & derivatives , Piperidines/therapeutic use , Sjogren's Syndrome/prevention & control , Administration, Topical , Animals , Cell Count , Dexamethasone/therapeutic use , Dry Eye Syndromes/genetics , Dry Eye Syndromes/pathology , Fluorescein/metabolism , Glucocorticoids/therapeutic use , Goblet Cells/pathology , Interleukin-1beta/genetics , Mice , Mice, Inbred C57BL , Nuclear Receptor Subfamily 1, Group F, Member 3/genetics , Ophthalmic Solutions , Phenylalanine/administration & dosage , Phenylalanine/therapeutic use , Piperidines/administration & dosage , RNA, Messenger/genetics , Real-Time Polymerase Chain Reaction , Sjogren's Syndrome/genetics , Sjogren's Syndrome/pathology , Staining and Labeling , Thrombospondin 1/deficiencyABSTRACT
An important role of transforming growth factor-ß (TGF-ß) in the development of regulatory T cells is well established. Although integrin-mediated activation of latent TGF-ß1 is considered essential for the induction of regulatory T (Treg) cells by antigen-presenting cells (APCs), such an activation mechanism is not applicable to the TGF-ß2 isoform, which lacks an integrin-binding RGD sequence in its latency-associated peptide. Mucosal and ocular tissues harbour TGF-ß2-expressing APCs involved in Treg induction. The mechanisms that regulate TGF-ß activation in such APCs remain unclear. In this study, we demonstrate that murine APCs exposed to TGF-ß2 in the environment predominantly increase expression of TGF-ß2. Such predominantly TGF-ß2-expressing APCs use thrombospondin-1 (TSP-1) as an integrin-independent mechanism to activate their newly synthesized latent TGF-ß2 to induce Foxp3(+) Treg cells both in vitro and in vivo. Expression of Treg induction by TGF-ß2-expressing APCs is supported by a TSP-1 receptor, CD36, which facilitates activation of latent TGF-ß during antigen presentation. Our results suggest that APC-derived TSP-1 is essential for the development of an adaptive regulatory immune response induced by TGF-ß2-expressing APCs similar to those located at mucosal and ocular sites. These findings introduce the integrin-independent mechanism of TGF-ß activation as an integral part of peripheral immune tolerance associated with TGF-ß2-expressing tissues.
Subject(s)
Antigen-Presenting Cells/immunology , Antigen-Presenting Cells/metabolism , Immunomodulation , Thrombospondin 1/metabolism , Transforming Growth Factor beta2/metabolism , Animals , Antigen-Presenting Cells/drug effects , CD36 Antigens/deficiency , CD36 Antigens/genetics , Forkhead Transcription Factors/genetics , Forkhead Transcription Factors/metabolism , Gene Expression , Immunomodulation/drug effects , Immunomodulation/genetics , Lymphocyte Activation/genetics , Lymphocyte Activation/immunology , Mice , Mice, Transgenic , T-Lymphocyte Subsets/immunology , T-Lymphocyte Subsets/metabolism , T-Lymphocytes, Regulatory/immunology , T-Lymphocytes, Regulatory/metabolism , Thrombospondin 1/deficiency , Thrombospondin 1/genetics , Transforming Growth Factor beta2/genetics , Transforming Growth Factor beta2/pharmacologyABSTRACT
Colorectal Cancer (CRC) is one of the late complications observed in patients suffering from inflammatory bowel diseases (IBD). Carcinogenesis is promoted by persistent chronic inflammation occurring in IBD. Understanding the mechanisms involved is essential in order to ameliorate inflammation and prevent CRC. Thrombospondin 1 (TSP-1) is a multidomain glycoprotein with important roles in angiogenesis. The effects of TSP-1 in colonic tumor formation and growth were analyzed in a model of inflammation-induced carcinogenesis. WT and TSP-1 deficient mice (TSP-1-/-) of the C57BL/6 strain received a single injection of azoxymethane (AOM) and multiple cycles of dextran sodium sulfate (DSS) to induce chronic inflammation-related cancers. Proliferation and angiogenesis were histologically analyzed in tumors. The intestinal transcriptome was also analyzed using a gene microarray approach. When the area containing tumors was compared with the entire colonic area of each mouse, the tumor burden was decreased in AOM/DSS-treated TSP-1-/- versus wild type (WT) mice. However, these lesions displayed more angiogenesis and proliferation rates when compared with the WT tumors. AOM-DSS treatment of TSP-1-/- mice resulted in significant deregulation of genes involved in transcription, canonical Wnt signaling, transport, defense response, regulation of epithelial cell proliferation and metabolism. Microarray analyses of these tumors showed down-regulation of 18 microRNAs in TSP-1-/- tumors. These results contribute new insights on the controversial role of TSP-1 in cancer and offer a better understanding of the genetics and pathogenesis of CRC.
Subject(s)
Carcinogenesis/metabolism , Carcinogenesis/pathology , Colorectal Neoplasms/metabolism , Colorectal Neoplasms/pathology , Thrombospondin 1/metabolism , Animals , Azoxymethane , Cell Proliferation , Colon/metabolism , Colon/pathology , Colorectal Neoplasms/blood supply , Colorectal Neoplasms/genetics , Dextran Sulfate , Disease Models, Animal , Down-Regulation/genetics , Gene Expression Regulation, Neoplastic , Genes, Neoplasm , Immunohistochemistry , Inflammation/pathology , Mice, Inbred C57BL , Microvessels/metabolism , RNA, Messenger/genetics , RNA, Messenger/metabolism , Reproducibility of Results , Thrombospondin 1/deficiency , Up-Regulation/geneticsABSTRACT
PURPOSE: The potential role of commensals as triggering factors that promote inflammation in dry eye disease has not been explored. The objective of this study was to evaluate whether ocular microbiota changes with the onset of dry eye disease in thrombospondin-1-deficient (TSP-1(-/-)) mice, a strain that develops Sjögren's syndrome-like disease. METHODS: Conjunctival swabs were collected from TSP-1(-/-) and C57BL/6 mice and analyzed for bacterial presence. Opsonophagocytosis of the bacterial conjunctival isolates derived from the aged TSP-1(-/-) mice by neutrophils derived from either TSP-1(-/-) or C57BL/6 bone marrow was evaluated. The bactericidal activities of TSP-1-derived peptide were examined. RESULTS: We found that in TSP-1(-/-) mice, the conjunctival colonization with Staphylococcus aureus and coagulase negative staphylococci sp (CNS) species was significantly increased with aging and preceded that of the wild-type C57BL/6 control mice. This correlated with increased neutrophil infiltration into the conjunctiva of the TSP-1(-/-) mice, suggesting that TSP-1 plays a significant role in regulating immunity to commensals. Accordingly, the TSP-1(-/-) PMNs opsonophagocytozed the ocular commensals less efficiently than the TSP-1-sufficient neutrophils. Furthermore, a TSP-1-derived peptide, 4N1K, exhibited significant antimicrobial activity when compared to a control peptide against commensal sp. CONCLUSION: These studies illustrate that alterations in the commensal frequency occur in the early stages of development of Sjögren's-like pathology and suggest that interventions that limit commensal outgrowth such as the use of TSP-1-derived peptides could be used for treatment during the early stages of the disease to reduce the commensal burden and ensuing inflammation.
Subject(s)
Microbiota , Sjogren's Syndrome/metabolism , Sjogren's Syndrome/microbiology , Thrombospondin 1/deficiency , Animals , Disease Models, Animal , Enzyme-Linked Immunosorbent Assay/methods , Eye/microbiology , Inflammation/microbiology , Inflammation/pathology , Male , Mice , Mice, Inbred C57BL , Mice, Transgenic , Sjogren's Syndrome/etiology , Sjogren's Syndrome/pathology , Staphylococcus aureus/growth & developmentABSTRACT
The development of a hyperexcitable neuronal network is thought to be a critical event in epilepsy. Thrombospondins (TSPs) regulate synaptogenesis by binding the neuronal α2δ subunit of the voltage-gated calcium channel. TSPs regulate synapse formation during development and in the mature brain following injury. It is unclear if TSPs are involved in hyperexcitability that contributes to the development of epilepsy. Here we explore the development of epilepsy using a pentylenetetrazole (PTZ) kindling model in mice lacking TSP1 and TSP2. Unexpectedly, we found increased sensitivity to PTZ kindling in mice lacking TSP1, while mice lacking TSP2 kindled similar to wild-type. We found that the increased seizure susceptibility in the TSP1 knockout (KO) mice was not due to a compensatory increase in TSP2 mRNA as TSP1/2 KO mice were sensitive to PTZ, similar to the TSP1 KO mice. Furthermore, there were similar levels of TGF-B signal activation during kindling in the TSP1 KO mice compared to wild-type. We observed decreased expression of voltage-dependent calcium channel subunit CACNA2D1 mRNA in TSP1, TSP2, and TSP1/2 KO mice. Decreased CACNA2D2 mRNA was only detected in mice that lacked TSP1 and α2δ-1/2 protein levels in the cortex were lower in the TSP 1/2 KO mice. CACNA2D2 knockout mice have spontaneous seizures and increased PTZ seizure susceptibility. Here we report similar findings, TSP1, and TSP1/2 KO mice have low levels of CACNA2D2 mRNA expression and α2δ-1/2 receptor level in the cortex, and are more susceptible to seizures. CACNA2D2 mutations in mice and humans can cause epilepsy. Our data suggest TSP1 in particular may control CACNA2D2 levels and could be a modifier of seizure susceptibility.